Matt Miksic

Stock Analyst at Barclays

(3.71)

# 723

Out of 4,931 analysts

290

Total ratings

57.83%

Success rate

3.49%

Average return

Main Sectors:

Top Industries:

Medical Devices Medical Instruments & Supplies Biotechnology Drug Manufacturers - General Medical Distribution

Stocks Rated by Matt Miksic

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BAX Baxter International	Maintains: Overweight	$41 → $36	$23.54	+52.93%	22	Aug 4, 2025
	ATEC Alphatec Holdings	Maintains: Overweight	$21 → $22	$14.90	+47.65%	3	Aug 4, 2025
	INMD InMode	Maintains: Overweight	$24 → $21	$14.37	+46.14%	14	Jul 30, 2025
	DXCM DexCom	Maintains: Equal-Weight	$93 → $98	$76.40	+28.27%	7	Jul 30, 2025
	EW Edwards Lifesciences	Maintains: Overweight	$90 → $95	$77.93	+21.90%	29	Jul 25, 2025
	BSX Boston Scientific	Maintains: Overweight	$125 → $133	$102.96	+29.18%	18	Jul 24, 2025
	ZIMV ZimVie	Upgrades: Equal-Weight	$9 → $19	$18.85	+0.80%	8	Jul 22, 2025
	JNJ Johnson & Johnson	Maintains: Equal-Weight	$165 → $176	$171.53	+2.61%	13	Jul 17, 2025
	BLCO Bausch + Lomb	Maintains: Equal-Weight	$19 → $16	$13.80	+15.94%	5	Jun 9, 2025
	BDX Becton, Dickinson and Company	Maintains: Overweight	$261 → $241	$187.68	+28.41%	1	Jun 3, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$56 → $55	$48.52	+13.36%	7	May 8, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$16 → $12	$2.60	+361.54%	2	May 5, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$234 → $266	$303.55	-12.37%	8	Apr 30, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$684 → $635	$469.81	+35.16%	7	Apr 24, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$158 → $159	$132.06	+20.40%	29	Apr 17, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$60 → $53	$11.52	+360.07%	6	Feb 28, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$100 → $103	$54.07	+90.49%	15	Feb 24, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Underweight	$118 → $112	$98.43	+13.79%	7	Feb 10, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$418 → $443	$376.37	+17.70%	23	Feb 10, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$22	$3.61	+509.42%	1	Jan 7, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$105 → $109	$91.24	+19.47%	21	Nov 26, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Assumes: Outperform	$96	$85.45	+12.35%	9	May 13, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Assumes: Outperform	$100	$65.90	+51.75%	8	May 13, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$722 → $418	$138.77	+201.22%	3	May 4, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$31 → $28	$11.22	+149.55%	2	Mar 2, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$68 → $67	$13.23	+406.42%	1	Mar 1, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Outperform	$480	$8.92	+5,281.17%	1	Jan 7, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$84 → $87	$12.64	+588.56%	14	Nov 3, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$24 → $25	$4.52	+453.10%	5	Aug 10, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Sell	$9	$7.11	+26.58%	1	Dec 12, 2016

Baxter International

Aug 4, 2025

Maintains: Overweight

Price Target: $41 → $36

Current: $23.54

Upside: +52.93%

Alphatec Holdings

Aug 4, 2025

Maintains: Overweight

Price Target: $21 → $22

Current: $14.90

Upside: +47.65%

InMode

Jul 30, 2025

Maintains: Overweight

Price Target: $24 → $21

Current: $14.37

Upside: +46.14%

DexCom

Jul 30, 2025

Maintains: Equal-Weight

Price Target: $93 → $98

Current: $76.40

Upside: +28.27%

Edwards Lifesciences

Jul 25, 2025

Maintains: Overweight

Price Target: $90 → $95

Current: $77.93

Upside: +21.90%

Boston Scientific

Jul 24, 2025

Maintains: Overweight

Price Target: $125 → $133

Current: $102.96

Upside: +29.18%

ZimVie

Jul 22, 2025

Upgrades: Equal-Weight

Price Target: $9 → $19

Current: $18.85

Upside: +0.80%

Johnson & Johnson

Jul 17, 2025

Maintains: Equal-Weight

Price Target: $165 → $176

Current: $171.53

Upside: +2.61%

Bausch + Lomb

Jun 9, 2025

Maintains: Equal-Weight

Price Target: $19 → $16

Current: $13.80

Upside: +15.94%

Becton, Dickinson and Company

Jun 3, 2025

Maintains: Overweight

Price Target: $261 → $241

Current: $187.68

Upside: +28.41%

May 8, 2025

Maintains: Equal-Weight

Price Target: $56 → $55

Current: $48.52

Upside: +13.36%

May 5, 2025

Maintains: Overweight

Price Target: $16 → $12

Current: $2.60

Upside: +361.54%

Apr 30, 2025

Maintains: Equal-Weight

Price Target: $234 → $266

Current: $303.55

Upside: -12.37%

Apr 24, 2025

Maintains: Overweight

Price Target: $684 → $635

Current: $469.81

Upside: +35.16%

Apr 17, 2025

Maintains: Overweight

Price Target: $158 → $159

Current: $132.06

Upside: +20.40%

Feb 28, 2025

Maintains: Overweight

Price Target: $60 → $53

Current: $11.52

Upside: +360.07%

Feb 24, 2025

Maintains: Overweight

Price Target: $100 → $103

Current: $54.07

Upside: +90.49%

Feb 10, 2025

Maintains: Underweight

Price Target: $118 → $112

Current: $98.43

Upside: +13.79%

Feb 10, 2025

Maintains: Overweight

Price Target: $418 → $443

Current: $376.37

Upside: +17.70%

Jan 7, 2025

Initiates: Overweight

Price Target: $22

Current: $3.61

Upside: +509.42%

Nov 26, 2024

Maintains: Overweight

Price Target: $105 → $109

Current: $91.24

Upside: +19.47%

May 13, 2022

Assumes: Outperform

Price Target: $96

Current: $85.45

Upside: +12.35%

May 13, 2022

Assumes: Outperform

Price Target: $100

Current: $65.90

Upside: +51.75%

May 4, 2022

Maintains: Outperform

Price Target: $722 → $418

Current: $138.77

Upside: +201.22%

Mar 2, 2022

Maintains: Outperform

Price Target: $31 → $28

Current: $11.22

Upside: +149.55%

Mar 1, 2022

Maintains: Outperform

Price Target: $68 → $67

Current: $13.23

Upside: +406.42%

Jan 7, 2022

Initiates: Outperform

Price Target: $480

Current: $8.92

Upside: +5,281.17%

Nov 3, 2021

Maintains: Outperform

Price Target: $84 → $87

Current: $12.64

Upside: +588.56%

Aug 10, 2021

Maintains: Outperform

Price Target: $24 → $25

Current: $4.52

Upside: +453.10%

Dec 12, 2016

Initiates: Sell

Price Target: $9

Current: $7.11

Upside: +26.58%